Semaglutide 2.4 mg, the approved dose for overweight/obesity management,18 is the most effective GLP‐1 receptor monoagonist, achieving 9.6% WL in individuals with T2D compared to 7% with the lower dose of 1 mg (which is approved for T2D management) and 3.4% with placebo.19 This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.